Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Zlatal
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Zlatal 20mg/0.8ml solution for injection pre-filled syringes
0801030P0BEAAFE
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 118 |
|
Zlatal 15mg/0.6ml solution for injection pre-filled syringes
0801030P0BEAGFK
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 93 |
|
Zlatal 25mg/1ml solution for injection pre-filled syringes
0801030P0BEACFG
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 48 |
|
Zlatal 10mg/0.4ml solution for injection pre-filled syringes
0801030P0BEADFH
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 34 |
|
Zlatal 7.5mg/0.3ml inj pre-filled syringes
0801030P0BEAEFI
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 28 |
|
Zlatal 17.5mg/0.7ml inj pre-filled syringes
0801030P0BEAHFL
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 23 |
|
Zlatal 22.5mg/0.9ml inj pre-filled syringes
0801030P0BEABFF
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 18 |
|
Zlatal 12.5mg/0.5ml inj pre-filled syringes
0801030P0BEAFFJ
|
Zlatal | Methotrexate | Malignant Disease and Immunosuppression | 16 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.